FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006452302> ?p ?o ?g. }

• W3006452302 abstract "Abstract Background Antimicrobial resistance is a growing threat to the world’s ability to prevent and treat infections. Links between quantitative antibiotic use and the emergence of bacterial resistance are well documented. This study presents benchmark antimicrobial use (AMU) rates for inpatient adult populations in acute-care hospitals across Canada. Methods In this retrospective surveillance study, acute-care adult hospitals participating in the Canadian Nosocomial Infection Surveillance Program (CNISP) submitted annual AMU data on all systemic antimicrobials from 2009 to 2016. Information specific to intensive care units (ICUs) and non-ICU wards were available for 2014–2016. Data were analyzed using defined daily doses (DDD) per 1000 patient days (DDD/1000pd). Results Between 2009 and 2016, 16–18 CNISP adult hospitals participated each year and provided their AMU data (22 hospitals participated in ≥1 year of surveillance; 11 in all years). From 2009 to 2016, there was a significant reduction in use (12%) (from 654 to 573 DDD/1000pd, p = 0.03). Fluoroquinolones accounted for the majority of this decrease (47% reduction in combined oral and intravenous use, from 129 to 68 DDD/1000pd, p < 0.002). The top five antimicrobials used in 2016 were cefazolin (78 DDD/1000pd), piperacillin-tazobactam (53 DDD/1000pd), ceftriaxone (49 DDD/1000pd), vancomycin (combined oral and intravenous use was 44 DDD/1000pd; 7% of vancomycin use was oral), and ciprofloxacin (combined oral and intravenous use: 42 DDD/1000pd). Among the top 10 antimicrobials used in 2016, ciprofloxacin and metronidazole use decreased significantly between 2009 and 2016 by 46% ( p = 0.002) and 26% ( p = 0.002) respectively. Ceftriaxone (85% increase, p = 0.0008) and oral amoxicillin-clavulanate (140% increase, p < 0.0001) use increased significantly but contributed only a small component (8.6 and 5.0%, respectively) of overall use. Conclusions This study represents the largest collection of dispensed antimicrobial use data among inpatients in Canada to date. Between 2009 and 2016, there was a significant 12% decrease in AMU, driven primarily by a 47% decrease in fluoroquinolone use. Modest absolute increases in parenteral ceftriaxone and oral amoxicillin-clavulanate use were noted but contributed a small amount of total AMU. Ongoing national surveillance is crucial for establishing benchmarks and antimicrobial stewardship guidelines." @default.
• W3006452302 created "2020-02-24" @default.
• W3006452302 creator A5002371143 @default.
• W3006452302 creator A5002378682 @default.
• W3006452302 creator A5002881838 @default.
• W3006452302 creator A5004823078 @default.
• W3006452302 creator A5009242761 @default.
• W3006452302 creator A5024423390 @default.
• W3006452302 creator A5027306439 @default.
• W3006452302 creator A5033340861 @default.
• W3006452302 creator A5035200491 @default.
• W3006452302 creator A5039379151 @default.
• W3006452302 creator A5041842577 @default.
• W3006452302 creator A5042035828 @default.
• W3006452302 creator A5043050509 @default.
• W3006452302 creator A5048365064 @default.
• W3006452302 creator A5052029507 @default.
• W3006452302 creator A5056071647 @default.
• W3006452302 creator A5059624007 @default.
• W3006452302 creator A5060834370 @default.
• W3006452302 creator A5065982970 @default.
• W3006452302 creator A5067447310 @default.
• W3006452302 creator A5067948987 @default.
• W3006452302 creator A5068926277 @default.
• W3006452302 creator A5070012747 @default.
• W3006452302 creator A5076068744 @default.
• W3006452302 creator A5078477133 @default.
• W3006452302 creator A5079876623 @default.
• W3006452302 creator A5081028585 @default.
• W3006452302 creator A5081394110 @default.
• W3006452302 creator A5085094236 @default.
• W3006452302 creator A5085654453 @default.
• W3006452302 creator A5089536235 @default.
• W3006452302 creator A5090380323 @default.
• W3006452302 creator A5091332556 @default.
• W3006452302 creator A5091335007 @default.
• W3006452302 date "2020-02-13" @default.
• W3006452302 modified "2023-10-18" @default.
• W3006452302 title "Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016" @default.
• W3006452302 cites W1539821149 @default.
• W3006452302 cites W1833417126 @default.
• W3006452302 cites W1981540326 @default.
• W3006452302 cites W2043089943 @default.
• W3006452302 cites W2055245456 @default.
• W3006452302 cites W2081380761 @default.
• W3006452302 cites W2093220053 @default.
• W3006452302 cites W2104518766 @default.
• W3006452302 cites W2105720008 @default.
• W3006452302 cites W2113403918 @default.
• W3006452302 cites W2119479710 @default.
• W3006452302 cites W2122173144 @default.
• W3006452302 cites W2147785741 @default.
• W3006452302 cites W2148440281 @default.
• W3006452302 cites W2162282209 @default.
• W3006452302 cites W2163392158 @default.
• W3006452302 cites W2168908910 @default.
• W3006452302 cites W2275388069 @default.
• W3006452302 cites W2524074902 @default.
• W3006452302 cites W2547759856 @default.
• W3006452302 cites W2555001236 @default.
• W3006452302 cites W2580443283 @default.
• W3006452302 cites W2747938232 @default.
• W3006452302 cites W2790528524 @default.
• W3006452302 cites W2791766793 @default.
• W3006452302 cites W2808799414 @default.
• W3006452302 cites W1926280277 @default.
• W3006452302 doi "https://doi.org/10.1186/s13756-020-0684-2" @default.
• W3006452302 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7020554" @default.
• W3006452302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32054539" @default.
• W3006452302 hasPublicationYear "2020" @default.
• W3006452302 type Work @default.
• W3006452302 sameAs 3006452302 @default.
• W3006452302 citedByCount "11" @default.
• W3006452302 countsByYear W30064523022021 @default.
• W3006452302 countsByYear W30064523022022 @default.
• W3006452302 countsByYear W30064523022023 @default.
• W3006452302 crossrefType "journal-article" @default.
• W3006452302 hasAuthorship W3006452302A5002371143 @default.
• W3006452302 hasAuthorship W3006452302A5002378682 @default.
• W3006452302 hasAuthorship W3006452302A5002881838 @default.
• W3006452302 hasAuthorship W3006452302A5004823078 @default.
• W3006452302 hasAuthorship W3006452302A5009242761 @default.
• W3006452302 hasAuthorship W3006452302A5024423390 @default.
• W3006452302 hasAuthorship W3006452302A5027306439 @default.
• W3006452302 hasAuthorship W3006452302A5033340861 @default.
• W3006452302 hasAuthorship W3006452302A5035200491 @default.
• W3006452302 hasAuthorship W3006452302A5039379151 @default.
• W3006452302 hasAuthorship W3006452302A5041842577 @default.
• W3006452302 hasAuthorship W3006452302A5042035828 @default.
• W3006452302 hasAuthorship W3006452302A5043050509 @default.
• W3006452302 hasAuthorship W3006452302A5048365064 @default.
• W3006452302 hasAuthorship W3006452302A5052029507 @default.
• W3006452302 hasAuthorship W3006452302A5056071647 @default.
• W3006452302 hasAuthorship W3006452302A5059624007 @default.
• W3006452302 hasAuthorship W3006452302A5060834370 @default.
• W3006452302 hasAuthorship W3006452302A5065982970 @default.
• W3006452302 hasAuthorship W3006452302A5067447310 @default.
• W3006452302 hasAuthorship W3006452302A5067948987 @default.
• W3006452302 hasAuthorship W3006452302A5068926277 @default.
• W3006452302 hasAuthorship W3006452302A5070012747 @default.

• next